In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clovis Oncology Inc.

www.clovisoncology.com

Latest From Clovis Oncology Inc.

What Late-Breakers To Look Out For At ASCO 2019

Delegates at this year’s ASCO meeting in Chicago will hear late-breaking clinical data for a number of studies from AstraZeneca, Novartis, Pfizer, Astellas, Merck & Co and Seattle Genetics which are set to shake up their respective markets. There will also be more clarity on where Lilly’s Lartruvo went so wrong.

ASCO Clinical Trials

Finance Watch: Five IPOs Launch In Two Days; Three Remain In Positive Territory

Public Company Edition: Trevi Therapeutics was the first out of the gate on 7 May, but four more biopharma firms went public in the US on 8 May, while just 13 IPOs launched between January and April. Also, new financings include debt for BMS, Bausch and Intercept.

Financing Business Strategies

Tesaro's On The Right Path With Anti-PD-1 Dostarlimab In Endometrial Cancer

Interview: Tesaro Chief Medical Officer Martin Huber addresses dostarlimab GARNET data and provides an update on integration with GlaxoSmithKline.

Research & Development Cancer

Merck KGAA/Pfizer Discontinue Phase III Avelumab/Talazoparib Combo Study In Ovarian Cancer

The changing competitive landscape in ovarian cancer, as well as disappointing earlier results in the condition, has led to the big pharma alliance ending the Phase III JAVELIN Ovarian PARP 100 study.

 

ImmunoOncology Research and Development Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Clovis Oncology Inc.
  • Senior Management
  • Patrick Mahaffy, Pres. & CEO
    Dan Muehl, EVP, Fin.
    Lindsey Rolfe, EVP, Clin. & Preclinical & Dev. & CMO
  • Contact Info
  • Clovis Oncology Inc.
    Phone: (303) 625-5000
    5500 Flatiron Parkway
    Boulder, CO 80301
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register